Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Interest Expenses (2016 - 2025)

Protalix BioTherapeutics has reported Interest Expenses over the past 13 years, most recently at $6000.0 for Q1 2025.

  • Quarterly results put Interest Expenses at $6000.0 for Q1 2025, down 98.46% from a year ago — trailing twelve months through Dec 2025 was $6000.0 (down 99.44% YoY), and the annual figure for FY2024 was $1.1 million, down 66.6%.
  • Interest Expenses for Q1 2025 was $6000.0 at Protalix BioTherapeutics, down from $41000.0 in the prior quarter.
  • Over the last five years, Interest Expenses for PLX hit a ceiling of $2.4 million in Q3 2021 and a floor of $6000.0 in Q1 2025.
  • Median Interest Expenses over the past 5 years was $639000.0 (2022), compared with a mean of $851235.3.
  • Biggest five-year swings in Interest Expenses: soared 109.47% in 2023 and later crashed 98.46% in 2025.
  • Protalix BioTherapeutics' Interest Expenses stood at $908000.0 in 2021, then fell by 28.41% to $650000.0 in 2022, then rose by 19.08% to $774000.0 in 2023, then plummeted by 94.7% to $41000.0 in 2024, then plummeted by 85.37% to $6000.0 in 2025.
  • The last three reported values for Interest Expenses were $6000.0 (Q1 2025), $41000.0 (Q4 2024), and $260000.0 (Q3 2024) per Business Quant data.